Atossa (ATOS) Reports Positive Results From EVANGELINE Study

Published on 11 Apr 2024 on Zacks via Yahoo Finance

Atossa (ATOS) Reports Positive Results From EVANGELINE Study

Atossa Therapeutics, Inc. ATOS recently announced promising safety and efficacy data from the company’s Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) clinical trial.

(Z)-endoxifen is being assessed as a neoadjuvant treatment for premenopausal women with Grade 1 or 2 Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer as part of the EVANGELINE research.

NASDAQ.ATOS price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Atossa Therapeutics Inc (ATOS) Q1 2024 Earnings: Aligns with Analyst Projections Amidst ...

Net Loss: Reported a net loss of $7.0 million for Q1 2024, slightly above the estimated net loss ...

GuruFocus.com via Yahoo Finance 15 May 2024

Atossa (ATOS) Reports Positive Results From EVANGELINE Study

Atossa Therapeutics, Inc. ATOS recently announced promising safety and efficacy data from the com...

Zacks via Yahoo Finance 11 Apr 2024

Atossa Therapeutics’ breast cancer drug milestone sparks investor enthusiasm

Atossa Therapeutics Inc (NASDAQ:ATOS) shares continued to move higher on Wednesday, buoyed by the...

Proactive Investors 20 Mar 2024

Atossa Therapeutics back in Nasdaq's good graces - Puget Sound Business Journal

Seattle-based biotech Atossa Therapeutics Inc. (Nasdaq: ATOS) has regained compliance with Nasdaq...

The Business Journals 19 Mar 2024

Atossa Therapeutics reports successful five-year treatment outcome for breast cancer patient using...

Atossa Therapeutics Inc (NASDAQ:ATOS), a company specializing in developing pharmaceuticals, has...

Proactive Investors 19 Mar 2024

Atossa reports successful 5-year breast cancer treatment By Investing.com

Atossa Therapeutics, Inc. (NASDAQ: ATOS), a clinical-stage biopharmaceutical company, announced...

Investing.com 19 Mar 2024

Atossa Therapeutics, Inc. (NASDAQ:ATOS): Is Breakeven Near?

We feel now is a pretty good time to analyse Atossa Therapeutics, Inc.'s (NASDAQ:ATOS) business a...

Simply Wall St. via Yahoo Finance 24 Jan 2024

10 Best Debt Free Penny Stocks To Buy Now

In this article we present the list of 10 Best Debt Free Penny Stocks To Buy Now. Click to skip o...

Insider Monkey via Yahoo Finance 4 Dec 2023

The 3 Best Biotech Stocks Under $1 to Buy for April

Typically, penny stocks are pure market wages for hardened gamblers. In fact, penny stocks are al...

InvestorPlace via Yahoo Finance 2 Apr 2023

Sinking stock threatens Atossa's place on the Nasdaq

Seattle-based biotech Atossa Therapeutics Inc. (Nasdaq: ATOS) faces delisting from the Nasdaq bec...

American City Business Journals 11 Oct 2022

News

Atossa (ATOS) Reports Positive Results From EVANGELINE Study

NASDAQ.ATOS price evolution

Want to become a better investor?